Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Convertible Debt (2016 - 2019)

BioCorRx (BICX) has disclosed Convertible Debt for 7 consecutive years, with $4.2 million as the latest value for Q4 2019.

  • Quarterly Convertible Debt changed N/A to $4.2 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Dec 2019, changed N/A year-over-year, with the annual reading at $4.2 million for FY2019, N/A changed from the prior year.
  • Convertible Debt hit $4.2 million in Q4 2019 for BioCorRx, roughly flat from $4.2 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $4.2 million in Q3 2019 to a low of $685.0 in Q3 2015.
  • Historically, Convertible Debt has averaged $1.3 million across 5 years, with a median of $791966.0 in 2016.
  • Biggest five-year swings in Convertible Debt: surged 73150.51% in 2016 and later skyrocketed 166.2% in 2018.
  • Year by year, Convertible Debt stood at $5530.0 in 2015, then skyrocketed by 12355.39% to $688783.0 in 2016, then skyrocketed by 192.7% to $2.0 million in 2017, then grew by 18.2% to $2.4 million in 2018, then soared by 74.58% to $4.2 million in 2019.
  • Business Quant data shows Convertible Debt for BICX at $4.2 million in Q4 2019, $4.2 million in Q3 2019, and $2.4 million in Q1 2018.